Charles River Clinical Services Northwest
Tacoma, Washington, 98403, United States
NCT Number: NCT00717262
The purpose of this study is to evaluate the safety, activity and pharmacokinetics of a new investigational drug (HQK-1001) in healthy human volunteers. This study will also evaluate if there are differences in these parameters when HQK-1001 is administered in a fed versus a fasted state.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Tacoma, Washington, 98403, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.
Matching placebo capsules administered once a day, orally, for 14 days.
Time frame: 41 days
Time frame: 15 days
Time frame: 41 days
Time frame: 41 days
Time frame: 41 days
HemaQuest Pharmaceuticals Inc.
Industry
A Phase 1, Double-Blind, Placebo Controlled, Repeat-Dose Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details